An Open-label, Randomized, Crossover, Two-period Study of the Comparative Pharmacokinetics and Bioequivalence of Doxylamine+Pyridoxine, 10 mg + 10 mg Enteric-soluble Film-coated Tablets (Valenta Pharm JSC, Russia) and Diclectin, 10 mg + 10 mg Delayed-release Tablets (Duchesnay Inc, Canada) Under Fed Conditions in Healthy Volunteers

Valenta Pharm JSC1 个研究点分布在 1 个国家目标入组 28 人开始时间: 2024年2月27日最近更新: 2025年7月11日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Valenta Pharm JSC
入组人数: 28
试验地点: 1
主要终点: Pharmacokinetics - AUC0-inf

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study aims to evaluate pharmacokinetic profile and establish bioequivalence of the investigational drug Doxylamine + Pyridoxine, enteric-soluble, film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSC, Russia) compared to the reference drug Diclectin, delayed-release tablets, 10 mg + 10 mg (registration certificate holder - Tzamal Bio-Pharma, Israel, manufacturer - Duchesnay Inc, Canada) in healthy volunteers under fed conditions.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Other
盲法: None

入排标准

年龄范围: 18 Years 至 49 Years（Adult）
性别: Female
接受健康志愿者: 是

入选标准

•Voluntary and personally signed informed consent form by the heathy subject prior to initiation of any study procedures.
•Women of childbearing potential (18 to 49 years inclusive).
•Verified "healthy" status with no abnormalities detected based on clinical, laboratory, and instrumental examinations specified in the study protocol.
•Blood pressure (BP) level: systolic blood pressure (SBP) from 100 to 139 mmHg, diastolic blood pressure (DBP) from 60 to 89 mmHg (inclusive).
•Heart rate (HR) from 60 to 90 beats per min (inclusive).
•Respiratory rate (RR) 12 to 18 breaths per min (inclusive).
•Body temperature from 36 to 36.9°C (inclusive).
•Body mass index (BMI) of 18.5 ≤ BMI ≤ 30 kg/m², with body weight ≥ 45 kg.
•Consent to use adequate contraceptive methods throughout the study and for 30 days after completion of the study, negative pregnancy test.
•Volunteers must demonstrate appropriate behavior and coherent speech.
•Non-inclusion Criteria:
•Positive allergic history.
•History of hypersensitivity to the active ingridient and/or excipients of the study drugs.
•A history of drug intolerance to the active ingridient and/or excipients of the study medications.
•Chronic diseases of cardiovascular, lymphatic, respiratory, nervous, endocrine, digestive, musculoskeletal, integumentary, immune systems, as well as genitourinary apparatus and hematopoietic organs.
•Clinically significant deviations from normal reference values for laboratory and diadnostic parameters based on local laboratory standarts.
•History of gastrointestinal tract surgery (excluding appendectomy performed at least 1 year prior to screening).
•Diseases/conditions that, in the investigator's judgement, may affect the absorption, distribution, metabolism, or excretion of study drugs.
•Acute infectious diseases within 4 weeks prior to screening.
•Use of medications with significant effects on hemodynamics or those affecting liver fuction (barbiturates, benzodiazepines, omeprazole, cimetidine, etc.) within 1 month prior to screening.
•Regular use of medicatins within 3 weeks prir to screening or single-dose medication intake within 7 days prior to screening.
•Blood or plasma donation within 3 months prior to the Screening Visit.
•Use of hormonal contraceptives within 2 months prior to the Screening Visit.
•Use of depot injections of any medications within 3 months prior to the Screening Visit.
•Pregnancy or lactation period, positive pregnancy test.
•Participation in another clinical trial less than 3 months prior to screening or concurrently with the present study.
•Consumption of more than 10 units of alcohol (1 unit of alcohol is equivalent to 500 mL of beer, 200 mL of wine, or 50 mL of spirits) per week in the last month prior to inclusion in the study or history of alcoholism, drug abuse, or medicines abuse.
•Positive blood test for antibodies to human immunodeficiency virus (HIV) types 1 and 2, antibodies to Treponema pallidum antigens, hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus antigens, rapid test (nasopharyngeal and/or oropharyngeal swab) for SARS-Cov-2 (COVID-19).
•Clinically significant abnormalities on electrocardiogram (ECG).
•Positive urinalysis for narcotics and potent drugs.
•Positive breath alcohol vapor test.
•Scheduling a hospital stay during the study period, for any reason other than hospitalization required by this protocol.
•Inability or inability to comply with the requirements of the protocol, to follow the procedures prescribed by the protocol, to follow the diet, activity regime.
•Observance of religious fasting or special diet (e.g., vegetarian, vegan).
•Other conditions that, in the Investigator's judgement, may interfere with the volunteer's participation in the study or lead to early withdrawal, including lifestyle factors such as night shift work or extreme physical exertion.
•Exclusion criteria
•Refusal by the volunteer to continue participation in the study.
•Failure of the volunteer to comply with study protocol requirements, including missed visits, unauthorized use of prohibited medications, or non-adherence to dietary and lifestyle restrictions.
•Occurrence of safety-related issues during the study that endanger the subject (e.g. hypersensitivity reactions, etc.).
•Volunteers included in the study in violation of the inclusion/non-inclusion criteria.
•Volunteer developing a severe and/or serious adverse event during the study.
•Missing collection of 2 or more consecutive blood samples, or 3 or more blood samples within a single period of pharmacokinetic part of the study.
•Occurrence of vomiting/diarrhea within 24 h after administration of the study drug (the choice of time interval is based on the value of tmax parameter for doxylamine and pyridoxal-5-phosphate, not exceeding 7.2 ± 1.9 and 11.7 ± 5.3 h, respectively, according to the manufacturer of the reference drug).
•Positive urine test for narcotics and potent drugs.
•Positive breath alcohol vapor test.
•A positive pregnancy test.
•A positive test for SARS-Cov-2 (COVID-19);
•Development of any new condition or situation that hinders protocol-defined procedures.

排除标准

未提供

研究组 & 干预措施

RT-sequence

Experimental

Group 1 (14 volunteers, RT sequence) will take 2 tablets of Diclectin in Period 1 and 2 tablets of Doxylamine + Pyridoxine in Period 2

干预措施: Doxylamine + Pyridoxine (Drug)

RT-sequence

Experimental

Group 1 (14 volunteers, RT sequence) will take 2 tablets of Diclectin in Period 1 and 2 tablets of Doxylamine + Pyridoxine in Period 2

干预措施: Diclectin (Drug)

TR-sequence

Active Comparator

Group 2 (14 volunteers, TR sequence) will take 2 tablets of Doxylamine + Pyridoxine in Period 1 and 2 tablets of Diclectin in Period 2

干预措施: Doxylamine + Pyridoxine (Drug)

TR-sequence

Active Comparator

Group 2 (14 volunteers, TR sequence) will take 2 tablets of Doxylamine + Pyridoxine in Period 1 and 2 tablets of Diclectin in Period 2

干预措施: Diclectin (Drug)